89BIO INC (ETNB) Stock Price, Quote, News and Overview
NASDAQ:ETNB - Nasdaq - US2825591033 - Common Stock - Currency: USD
ETNB Quote, Performance and Key Statistics
89BIO INC
NASDAQ:ETNB (1/24/2025, 8:00:02 PM)
After market: 7.5 +0.37 (+5.19%)7.13
+0.21 (+3.03%)
The current stock price of ETNB is 7.13 USD. In the past month the price decreased by -10.76%. In the past year, price decreased by -29.89%.
ETNB Latest News, Press Releases and Analysis
Friday's after hours session: top gainers and losers
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
89bio Provides Business Update and Outlook for 2025
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company...
ETNB Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.84 | 300.94B | ||
| AMGN | AMGEN INC | 14.33 | 148.05B | ||
| GILD | GILEAD SCIENCES INC | 21.01 | 115.99B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 862 | 113.22B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.88 | 74.26B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.80B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.47B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.64B | ||
| NTRA | NATERA INC | N/A | 22.13B | ||
| BIIB | BIOGEN INC | 8.95 | 21.30B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.52B |
Related stock screener links
About ETNB
Company Profile
89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company is headquartered in San Francisco, California and currently employs 70 full-time employees. The company went IPO on 2019-11-11. The firm is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone. The company conducted a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics (PK) of pegozafermin.
Company Info
89BIO INC
142 Sansome Street, Second Floor
San Francisco CALIFORNIA 94104 US
CEO: Rohan Palekar
Employees: 70
Company Website: https://www.89bio.com/
Investor Relations: https://ir.89bio.com/
Phone: 14154329270
ETNB FAQ
What is the stock price of ETNB?
The current stock price of ETNB is 7.13 USD.
What is the symbol for 89BIO INC stock?
The exchange symbol of 89BIO INC is ETNB and it is listed on the Nasdaq exchange.
On which exchange is ETNB stock listed?
ETNB stock is listed on the Nasdaq exchange.
Is ETNB a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ETNB, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ETNB.
Does ETNB stock pay dividends?
ETNB does not pay a dividend.
What is the Price/Earnings (PE) ratio of ETNB?
ETNB does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.91).
What is the Short Interest ratio of ETNB stock?
The outstanding short interest for ETNB is 6.75% of its float.
ETNB Technical Analysis
ETNB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ETNB. ETNB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ETNB Financial Highlights
Over the last trailing twelve months ETNB reported a non-GAAP Earnings per Share(EPS) of -2.91. The EPS decreased by -46.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -63.05% | ||
| ROE | -76.42% | ||
| Debt/Equity | 0.09 |
ETNB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ETNB. The Buy consensus is the average rating of analysts ratings from 15 analysts.